| Primary |
| Cellulitis |
17.5% |
| Fungal Infection |
12.5% |
| Product Used For Unknown Indication |
12.5% |
| Arthritis |
5.0% |
| Aspiration |
5.0% |
| Bacterial Infection |
5.0% |
| Infected Skin Ulcer |
5.0% |
| Meningitis Meningococcal |
5.0% |
| Vasculitis |
5.0% |
| Anaphylactic Reaction |
2.5% |
| Blister |
2.5% |
| Bunion Operation |
2.5% |
| Cardiovascular Disorder |
2.5% |
| Deep Vein Thrombosis |
2.5% |
| Hypercholesterolaemia |
2.5% |
| Hypertension |
2.5% |
| Hypotension |
2.5% |
| Infection |
2.5% |
| Migraine |
2.5% |
| Osteomyelitis |
2.5% |
|
| Diarrhoea |
27.3% |
| Cardiac Murmur |
9.1% |
| Fungal Infection |
9.1% |
| Jaundice Cholestatic |
9.1% |
| Melaena |
9.1% |
| Metabolic Acidosis |
9.1% |
| Myocardial Infarction |
9.1% |
| Staphylococcal Skin Infection |
9.1% |
| Vomiting |
9.1% |
|
| Secondary |
| Product Used For Unknown Indication |
41.8% |
| Cellulitis |
9.0% |
| Fungal Infection |
8.3% |
| Drug Use For Unknown Indication |
3.8% |
| Pneumonia |
3.5% |
| Antibiotic Therapy |
3.4% |
| Sepsis |
3.3% |
| Anaesthesia |
3.0% |
| Urinary Tract Infection |
3.0% |
| Acarodermatitis |
2.5% |
| Induction Of Anaesthesia |
2.5% |
| Infection |
2.2% |
| Osteomyelitis |
2.2% |
| Abscess Limb |
2.1% |
| Antibiotic Prophylaxis |
2.1% |
| Postoperative Care |
1.7% |
| Pyrexia |
1.6% |
| Psoas Abscess |
1.5% |
| Wound Infection |
1.4% |
| Ulcer |
1.3% |
|
| Diarrhoea |
13.7% |
| Rhabdomyolysis |
11.1% |
| Clostridium Test Positive |
7.8% |
| Renal Failure Acute |
5.9% |
| Vomiting |
5.9% |
| Oedema Peripheral |
5.2% |
| Clostridium Difficile Infection |
4.6% |
| Fungal Infection |
4.6% |
| Liver Function Test Abnormal |
4.6% |
| Metabolic Acidosis |
4.6% |
| Treatment Failure |
4.6% |
| Thrombocytopenia |
3.9% |
| Urosepsis |
3.9% |
| Eosinophil Count Abnormal |
3.3% |
| Pregnancy With Injectable Contraceptive |
3.3% |
| Anaphylactic Reaction |
2.6% |
| Blindness |
2.6% |
| Blister |
2.6% |
| Gastrointestinal Hypermotility |
2.6% |
| Hepatitis Cholestatic |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
57.0% |
| Drug Use For Unknown Indication |
5.9% |
| Infection |
3.8% |
| Hypercholesterolaemia |
3.2% |
| Pain |
3.1% |
| Prophylaxis |
3.0% |
| Rheumatoid Arthritis |
2.7% |
| Osteomyelitis |
2.6% |
| Nausea |
2.4% |
| Cellulitis |
2.2% |
| Hypertension |
1.9% |
| Anxiety |
1.8% |
| Depression |
1.5% |
| Anaemia |
1.5% |
| Psoas Abscess |
1.5% |
| B-cell Lymphoma |
1.2% |
| Staphylococcal Infection |
1.2% |
| Chronic Obstructive Pulmonary Disease |
1.1% |
| Localised Infection |
1.1% |
| Osteomyelitis Chronic |
1.1% |
|
| Rhabdomyolysis |
17.9% |
| Vomiting |
9.9% |
| Renal Failure Acute |
9.5% |
| Dyspnoea |
7.3% |
| Rash |
7.0% |
| Sepsis |
6.2% |
| Wheezing |
4.4% |
| Death |
3.7% |
| Thrombocytopenia |
3.7% |
| Pain |
3.3% |
| Paraesthesia |
3.3% |
| Tachycardia |
3.3% |
| Cellulitis |
2.9% |
| Urinary Tract Infection |
2.9% |
| Abdominal Pain |
2.6% |
| Infection |
2.6% |
| Malaise |
2.6% |
| Stevens-johnson Syndrome |
2.6% |
| Deep Vein Thrombosis |
2.2% |
| Distal Intestinal Obstruction Syndrome |
2.2% |
|
| Interacting |
| Erythrodermic Psoriasis |
10.7% |
| Impetigo |
10.7% |
| Sepsis |
10.7% |
| Epilepsy |
8.0% |
| Chronic Obstructive Pulmonary Disease |
5.3% |
| Osteomyelitis |
5.3% |
| Product Used For Unknown Indication |
5.3% |
| Psoriasis |
5.3% |
| Staphylococcal Infection |
5.3% |
| Arthralgia |
4.0% |
| Procedural Pain |
4.0% |
| Wound Complication |
4.0% |
| Atrial Fibrillation |
2.7% |
| Cellulitis |
2.7% |
| Deep Vein Thrombosis |
2.7% |
| Hypercholesterolaemia |
2.7% |
| Infection |
2.7% |
| Joint Arthroplasty |
2.7% |
| Osteoarthritis |
2.7% |
| Smoking Cessation Therapy |
2.7% |
|
| Rhabdomyolysis |
21.4% |
| Metabolic Acidosis |
14.3% |
| Arthritis Infective |
10.7% |
| Atrial Fibrillation |
7.1% |
| Drug Interaction |
7.1% |
| Drug Level Below Therapeutic |
7.1% |
| Pyrexia |
7.1% |
| Vasculitis |
7.1% |
| Depressed Level Of Consciousness |
3.6% |
| Embolic Stroke |
3.6% |
| Hypersensitivity |
3.6% |
| International Normalised Ratio Decreased |
3.6% |
| Urticaria |
3.6% |
|
